Head-To-Head Survey: Pulmatrix (PULM) versus The Competition

Pulmatrix (NASDAQ: PULM) is one of 491 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Pulmatrix to related businesses based on the strength of its earnings, analyst recommendations, profitability, risk, institutional ownership, valuation and dividends.

Volatility & Risk

Get Pulmatrix alerts:

Pulmatrix has a beta of 2.74, meaning that its share price is 174% more volatile than the S&P 500. Comparatively, Pulmatrix’s rivals have a beta of 1.09, meaning that their average share price is 9% more volatile than the S&P 500.

Valuation and Earnings

This table compares Pulmatrix and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Pulmatrix	$340,000.00	-$18.05 million	-0.48
Pulmatrix Competitors	$2.01 billion	$135.87 million	-3.38

Pulmatrix’s rivals have higher revenue and earnings than Pulmatrix. Pulmatrix is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Pulmatrix and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulmatrix	N/A	-171.39%	-109.20%
Pulmatrix Competitors	-2,958.10%	-158.97%	-30.57%

Insider and Institutional Ownership

18.6% of Pulmatrix shares are owned by institutional investors. Comparatively, 47.5% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 26.0% of Pulmatrix shares are owned by company insiders. Comparatively, 15.6% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Pulmatrix and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmatrix	0	0	2	0	3.00
Pulmatrix Competitors	2998	9071	22008	625	2.58

Pulmatrix currently has a consensus price target of $3.00, indicating a potential upside of 569.79%. As a group, “Pharmaceutical preparations” companies have a potential upside of 42.33%. Given Pulmatrix’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Pulmatrix is more favorable than its rivals.

Summary

Pulmatrix beats its rivals on 7 of the 13 factors compared.

Pulmatrix Company Profile

Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, including asthma and chronic obstructive pulmonary disease (COPD). The company is also involved in developing PUR0200, a reformulation of an existing long-acting antimuscarinic agent that has completed Phase Ib clinical development, which blocks the effects of acetylcholine on muscarinic receptors to reverse airway obstruction in COPD patients. It has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates; and a partnership agreement with Vectura Group plc to develop its drug candidate. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.